Literature DB >> 10589757

Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.

Z Duan1, A J Feller, R T Penson, B A Chabner, M V Seiden.   

Abstract

In an attempt to define the molecular changes associated with the paclitaxel-resistant phenotype in human cancer, a paclitaxel-resistant ovarian cancer cell line, SKOV-3TR, was established through stepwise selection in increasing paclitaxel concentrations. SKOV-3TR was cross- resistant to doxorubicin and vincristine and overexpressed multidrug resistance gene 1 but not multidrug resistance associated protein. SKOV-3TR and the paclitaxel-sensitive SKOV-3 parent line were characterized using human cDNA array technology that examined expression of a wide variety of genes involved in cell growth, signal transduction, cell death, and immune function. cDNA probes from reverse transcribed mRNAs of both paclitaxel-resistant and parent cells were compared to identify genes differentially expressed in the paclitaxel-resistant cells. Of 588 different human cDNA transcripts compared, 6 genes were found to be markedly decreased, and 12 genes increased in the resistant subline. Northern analysis and/or reverse transcription-PCR confirmed that 12 of these 18 genes were over- or underexpressed in SKOV-3TR. In addition, at least eight of the genes were found differentially expressed in several other paclitaxel- and/or doxorubicin-resistant cell lines, both those with increased multidrug resistance expression and those without. Included in the set of overexpressed genes were the cytokines/chemokines interleukin 6, interleukin 8, and monocyte chemotactic protein 1. ELISA assays confirm that mRNA overexpression of these cytokine/chemokines was associated with the increased secretion of these molecules in the tissue culture supernatant. Evaluation of supernatants from an expanded collection of paclitaxel- and Adriamycin-resistant cell lines demonstrated that all of the resistant lines had significant overexpression of at least one cytokine/chemokine as compared with their drug-sensitive parent line. The overexpression of these cytokines seemed to be stable and associated with a drug-resistant phenotype with only a modest induction of cytokine expression in the parent line with short-term paclitaxel exposure. These findings suggest that the development of paclitaxel resistance is accompanied by multiple changes in gene expression including stable alterations in selective chemokine and cytokine expression. The role these associated genetic changes have in the drug-resistant phenotype is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589757

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

1.  Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions.

Authors:  Jay F Dorsey; Melissa L Dowling; Mijin Kim; Ranh Voong; Lawrence J Solin; Gary D Kao
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

2.  Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.

Authors:  Carin K Ingemarsdotter; Laura A Tookman; Ashley Browne; Katrina Pirlo; Rosalind Cutts; Claude Chelela; Karisma F Khurrum; Elaine Y L Leung; Suzanne Dowson; Lee Webber; Iftekhar Khan; Darren Ennis; Nelofer Syed; Tim R Crook; James D Brenton; Michelle Lockley; Iain A McNeish
Journal:  Mol Oncol       Date:  2014-12-29       Impact factor: 6.603

Review 3.  The Role of TLR4 in Chemotherapy-Driven Metastasis.

Authors:  Sophia Ran
Journal:  Cancer Res       Date:  2015-05-21       Impact factor: 12.701

4.  Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.

Authors:  Sharon Cohen; Ilan Bruchim; Dror Graiver; Zoharia Evron; Varda Oron-Karni; Metsada Pasmanik-Chor; Ram Eitan; Joelle Bernheim; Hanoch Levavi; Ami Fishman; Eliezer Flescher
Journal:  J Mol Med (Berl)       Date:  2012-09-28       Impact factor: 4.599

5.  Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.

Authors:  Francois Moisan; Edgar B Francisco; Anamaria Brozovic; George E Duran; Yan C Wang; Shalini Chaturvedi; Shobha Seetharam; Linda A Snyder; Parul Doshi; Branimir I Sikic
Journal:  Mol Oncol       Date:  2014-04-18       Impact factor: 6.603

Review 6.  The immune system in the pathogenesis of ovarian cancer.

Authors:  Bridget Charbonneau; Ellen L Goode; Kimberly R Kalli; Keith L Knutson; Melissa S Derycke
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

Review 7.  Using space-based investigations to inform cancer research on Earth.

Authors:  Jeanne L Becker; Glauco R Souza
Journal:  Nat Rev Cancer       Date:  2013-04-12       Impact factor: 60.716

8.  Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.

Authors:  Yilin Zhang; Shravan Kumar Sriraman; Hilary A Kenny; Ed Luther; Vladimir Torchilin; Ernst Lengyel
Journal:  Mol Cancer Ther       Date:  2016-07-27       Impact factor: 6.261

9.  CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.

Authors:  Zhenfeng Duan; Rachel Y Ames; Meagan Ryan; Francis J Hornicek; Henry Mankin; Michael V Seiden
Journal:  Cancer Chemother Pharmacol       Date:  2008-06-28       Impact factor: 3.333

10.  ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.

Authors:  Zhenfeng Duan; Edwin Choy; David Harmon; Cao Yang; Keinosuke Ryu; Joseph Schwab; Henry Mankin; Francis J Hornicek
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.